Solana Company - Class A (HSDT)

Looking at the transition from medical devices to a pure-play digital asset treasury, our fund sees HSDT essentially acting as a proxy vehicle for Solana exposure. The pivot is aggressive, marked by Joseph Chee's appointment as Executive Chairman and over $500 million raised in private placements. However, sentiment is heavily split given the massive historical stock decline and the fact that quarterly results are entirely dictated by the fluctuating market value of their SOL holdings.

On our risk desk, HSDT represents a high-beta volatility play. The Q1 2026 net loss of $99.8 million highlights the direct peril of holding millions of SOL tokens on the balance sheet when cryptocurrency prices drop. Even though they successfully divested the PoNS medical device business for $5 million upfront and earnouts, operating costs and severance expenses continue to pressure the bottom line severely.

Our quantitative model flags severe structural risks regarding asset concentration. As of March 31, 2026, digital asset exposure represented 85.8% of total assets, with over 2 million SOL tokens held. Management claims liquidity is sufficient through May 2027, but that projection relies entirely on their ability to opportunistically liquidate digital assets in adverse market conditions without triggering a liquidity spiral.

From a clinical and legacy asset perspective, the complete divestiture of the PoNS medical device business—including the $6.8 million in severance tied to the wind-down—marks the definitive end of HSDT's healthcare era. Analysts evaluating past operations must completely recalibrate financial models to focus on digital asset yields, staking economics, and liquidity runways rather than medical device commercialization milestones.

As a bio-analyst reviewing legacy coverage, the complete removal of FDA-regulated medical technology from HSDT's portfolio means traditional healthcare risk factors are entirely obsolete. The new paradigm is dictated by digital asset collateral receivables, restricted digital tokens, and crypto market cycles. Any future valuation must be tied strictly to their treasury execution and validator staking yields.

On our options desk, trading HSDT requires extreme caution given the historical 1-for-50 reverse stock split and the severe 52-week drawdown. While the company reported a massive jump in Q2 staking revenue to $2.5 million with a 97% gross margin, general and administrative expenses of $11.1 million and a net operating loss of $35.1 million show that corporate overhead remains bloated during this transitional phase.